Tag:

Roche

Latest Headlines

Latest Headlines

Who are the stars of personalized meds? Roche, Novartis and J&J

Targeted drugs, personalized medicine, stratified therapy--whatever you call it, using biomarkers to identify particular patients for particular drugs has been hailed as a boon for patients and a savvy strategy for pharma.

Who are the stars of personalized medicine? Roche, Novartis and J&J

The star of personalized medicine is just the company you'd expect: Roche, with its drug-plus-diagnostic approach to cancer R&D and its stable of blockbuster HER2-positive therapies, and a total of almost $20 billion in sales from its targeted drugs.

Cambrian raises $10M for DNA printing tech used by GSK

Proponents of DNA printing have heralded it as a way to do everything from bringing alien life back from Mars to delivering vaccines in the event of a pandemic. And the technology has attracted GlaxoSmithKline and Roche, both of which have taken an interest in Cambrian Genomics.

Doc coughs up $2M for using unapproved Avastin on his cancer patients

A U.S. oncologist who thought he was getting a great deal on drugs that were almost the same thing as Avastin has found they will cost him an extra $2 million and a federal misdemeanor conviction.

Interpol: Organized crime, aware of weak points, targets counterfeit drugs

Organized crime has moved into selling counterfeit and compromised prescription drugs in Europe, exploiting the mishmash of customs laws and weak points in some border protection. Those weaknesses allowed the "Mafia" to get fake manifests, use suspect wholesalers, and sell counterfeits of Roche's Herceptin and other cancer drugs across Europe.

NICE asks Novartis to pony up more information on Xolair for hives

The U.K.'s cost-effectiveness gatekeepers have flip-flopped on Novartis' Xolair before, withdrawing support for the drug in 2012 before expanding its approval for asthma the following year. Now, the National Institute for Health and Clinical is asking the drugmaker to pony up more information about the product before recommending it to treat chronic spontaneous urticarial (CSU), or psoriasis.

Roche nabs FDA clearance for quick strep test

A new test that aims to cut down the time it takes to diagnose strep throat is expected to hit the market by year's end.

Roche's Avastin wins FDA green light in ovarian cancer

Roche's Avastin is now two-for-two on converting recent FDA priority review designations into label expansions. Just three months after the cancer giant nabbed the agency's blessing for use in cervical cancer, regulators have approved the drug in combination with chemotherapy as a treatment for platinum-resistant, recurrent ovarian cancer.

Genentech R&D team fixes a flawed approach to Alzheimer's

Roche never publicly described what went wrong with its early-stage BACE drug for Alzheimer's when it killed the program. But a new study from the pharma giant's Genentech unit outlines the potential threat one of their BACE efforts posed to patients--and how they've managed to adjust for it in animal studies that may well open the door to new human trials.

Roche sets its sails toward China with new Dx manufacturing facility

Roche is casting its sails toward China, eyeing the country's growing diagnostic market with plans for a new diagnostic manufacturing facility.